Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Success Reported During Phase III Trial For Neurological Disorder Treatment

By Mike Botta | November 30, 2017

Pharnext: Successful intermediate analyses for PLEO-CMT Phase III clinical trial in Charcot-Marie-Tooth disease Type 1A.

Pharnext SA, a biopharmaceutical company working on a new approach for the development of drugs based on the combination and repositioning of known therapies, announced successful intermediate analyses for its Phase III clinical trial, PLEO-CMT, in Charcot-Marie-Tooth Disease Type 1A (CMT1A).

The ongoing study is part of a new company paradigm called PLEOTHERAPY, which centers on a blending of drugs previously established and targeted for the treatment of certain disorders that, when combined in optimal lower doses, can be repositioned and formulated into new, effective therapies for fighting other maladies, such as Alzheimer’s disease.

PLEO-CMT is a pivotal, multi-center, randomized, 15 months, double blind, placebo-controlled Phase III study that was initiated in December 2015 and has enrolled 323 patients with mild-to-moderate CMT1A in 30 sites across Europe, the U.S., and Canada.

With completion of the study expected by the end of next year, two intermediate analyses — a blind variability analysis followed by a futility analysis — were carried out as planned.

See related article on PLEOTHERAPY: “Two Drugs Can Be Better Than One,” an in-depth report featuring Rodolphe Hajj, Ph.D., chief pharmacology officer at Pharnext.

According to Professor Philippe Lehert, member of the independent Data Safety Monitoring Board, the variability of tests between patients is within predefined limits. In addition, a futility analysis concluded that PLEO-CMT is sufficiently powered to detect an effect of Pharnext’s lead PLEODRUG —PXT3003 — on the primary efficacy endpoint.

The Data Safety Monitoring Board is an independent body of experts drawn from the fields of clinical medicine, biostatistics, and study methodology, chartered to provide recommendations to Pharnext upon regular pre-specified review of the accumulated data during the conduct of the clinical trial.

The analyses follow two favorable intermediate safety analyses delivered by the monitoring board in November 2016 and September 2017 and indicate that PLEO-CMT can continue according to the original plan without having to increase the trial size, according to the company.

Final results of the study are expected in the second half of 2018.

(Source: Pharnext SA; Pictured: Pharnext headquarters in the southwestern suburban area of Paris, France, courtesy Pharnext)


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE